Pramlintide
TOTT
AstraZeneca · Phase 2/3 · Withdrawn · Enrollment 0
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Semaglutide and placebo | Obesity + T2D | n/r | 26 | n/r | n/r |
| Semaglutide and pramlintide | Obesity + T2D | n/r | 26 | n/r | n/r |
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
Pramlintide
AstraZeneca · Phase 2/3 · Withdrawn · Enrollment 0
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Semaglutide and placebo | Obesity + T2D | n/r | 26 | n/r | n/r |
| Semaglutide and pramlintide | Obesity + T2D | n/r | 26 | n/r | n/r |